Splenomegaly-associated thrombocytopenia after hepatic yttrium-90 radioembolization

CardioVascular and Interventional Radiology

Volumn 37, Issue 4, 2014, Pages 1009-1017

  Lam, Marnix G E H ^a,b   Banerjee, Arjun ^a   Louie, John D ^a   Sze, Daniel Y ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Liver; Platelets; Radioembolization; Spleen; Thrombocytopenia; Toxicity

Indexed keywords

BEVACIZUMAB; IRINOTECAN; OXALIPLATIN; SORAFENIB; YTTRIUM 90; MICROSPHERE; YTTRIUM;

ADULT; AGED; ARTICLE; BODY SURFACE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DOSE CALCULATION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; HYPERSPLENISM; INTERNATIONAL NORMALIZED RATIO; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; NEUTROPHIL COUNT; PATIENT SELECTION; PORTAL HYPERTENSION; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOEMBOLIZATION; RISK FACTOR; SPLEEN SIZE; SPLENOMEGALY; SPLENOMEGALY ASSOCIATED THROMBOCYTOPENIA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ADVERSE EFFECTS; ARTIFICIAL EMBOLISM; DIAGNOSTIC IMAGING; LIVER NEOPLASMS; MIDDLE AGED; RADIATION DOSE; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DIAGNOSTIC IMAGING; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SPLENOMEGALY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84904465950     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-013-0742-8     Document Type: Article

References (31)

1. Riaz A, Lewandowski RJ, Kulik LM et al (2009) Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 20:1121-1130
2. Carr BI (2004) Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 10:S107-S110
3. Salem R, Lewandowski RJ, Atassi B et al (2005) Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16:1627-1639 (Pubitemid 44431160)
4. Novell JR, Hilson A, Hobbs KE (1991) Therapeutic aspects of radio-isotopes in hepatobiliary malignancy. Br J Surg 78:901-906
5. Lawrence TS, Robertson JM, Anscher MS et al (1995) Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31:1237-1248
6. Jakobs TF, Saleem S, Atassi B et al (2008) Fibrosis, portal hypertension, and hepatic volume changes induced by intraarterial radiotherapy with 90yttrium microspheres. Dig Dis Sci 53:2556-2563
7. Nosher JL, Ohman-Strickland PA et al (2011) Changes in liver and spleen volumes and liver function after radioembolization with yttrium-90 resin microspheres. J Vasc Interv Radiol 22:1706-1713
8. Paprottka PM, Schmidt GP, Trumm CG et al (2011) Changes in normal liver and spleen volume after radioembolization with (90)Y-resin microspheres in metastatic breast cancer patients: findings and clinical significance. Cardiovasc Intervent Radiol 34:964-972
9. Nijsen JF, van het Schip AD, Hennink WE et al (2002) Advances in nuclear oncology: microspheres for internal radionuclide therapy of liver tumours. Curr Med Chem 9:73-82 (Pubitemid 34441017)
10. Coldwell D, Sangro B, Wasan H et al (2011) General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am J Clin Oncol 34:337-341
11. Dezarn WA, Cessna JT, de Werd LA et al (2011) Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys 38:4824-4845
12. Kennedy A, Nag S, Salem R et al (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68:13-23 (Pubitemid 46589861)
13. Gulec SA, Mesoloras G, Stabin M (2006) Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med 47:1209-1211 (Pubitemid 47544917)
14. Yang CW, Yen HH, Su WW et al (2010) Profound transient thrombocytopenia associated with 90-yttrium microsphere therapy for inoperable hepatoma. South Med J 103:1264-1268
15. Lambert B, Sturm E, Mertens J et al (2011) Intra-arterial treatment with (90)Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. Eur J Nucl Med Mol Imaging 38:2117-2124
16. Laznicek M, Laznickova A, Macke HR et al (2002) Octreotide and octreotate derivatives radiolabeled with yttrium: pharmacokinetics in rats. Cancer Biother Radiopharm 17:527-533 (Pubitemid 35231612)
17. Hirano S, Kodama N, Shibata K et al (1993) Metabolism and toxicity of intravenously injected yttrium chloride in rats. Toxicol Appl Pharmacol 121:224-232 (Pubitemid 23227738)
18. Kutzner J, Becker M, Grimm W (1983) Bone-seeking behavior of rhenium and yttrium complexes. Nuklearmedizin 22:162-165 (Pubitemid 13000379)
19. Baechler S, Hobbs RF, Jacene HA et al (2010) Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. J Nucl Med 51:1878-1884
20. Fajardo LF, Colby TV (1980) Pathogenesis of veno-occlusive liver disease after radiation. Arch Pathol Lab Med 104:584-588 (Pubitemid 11240975)
21. Kennedy AS, McNeillie P, Dezarn WA et al (2009) Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 74:1494-1500
22. Moroz P, Anderson JE, van Hazel GA, Gray BN (2001) Effect of selective internal radiation therapy and hepatic arterial chemotherapy on normal liver volume and spleen volume. J Surg Oncol 78:248-252 (Pubitemid 33097055)
23. Sharma RA, van Hazel GA, Morgan B et al (2007) Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 25:1099-1106 (Pubitemid 46596762)
24. Seidensticker R, Seidensticker M, Damm R et al (2012) Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: Sequential lobar versus whole liver approach. Cardiovasc Intervent Radiol 35:1109-1118
25. Ahmadzadehfar H, Meyer C, Ezziddin S et al (2013) Hepatic volume changes induced by radioembolization with (90)Y resin microspheres. A single-centre study. Eur J Nucl Med Mol Imaging 40:80-90
26. Harandi A, Zaidi AS, Stocker AM, Laber DA (2009) Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol 2009:567486
27. Fernandez-Ros N, Silva N, Bilbao JI, et al. (2013) Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. HPB (Oxford). doi:10.1111/hpb.12095
28. Ayav A, Habib N, Jiao LR (2005) Portal hypertension secondary to 90-Yttrium microspheres: an unknown complication. J Clin Oncol 23:8275-8276 (Pubitemid 46211568)
29. Stubbs RS (2006) Portal hypertension and liver surgery following selective internal radiation therapy with 90-Yttrium microspheres. J Clin Oncol 24:e15
30. Lau WY, Kennedy AS, Kim YH et al (2012) Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 82:401-407
31. Rodrigues M, Sinzinger H (1994) Platelet labeling methodology and clinical applications. Thromb Res 76:399-432